Inflation, Biosimilars, And The Wizard Of Oz: An Interview With Teva’s Christine Baeder

The new chair of the US generics association talks to the Pink Sheet about how to make sure that policymakers don’t take the industry for granted.

tornado
Bad news for antibiotics? • Source: Shutterstock

Christine Baeder, Teva Pharmaceutical Industries Ltd.’s senior vice president and chief operating officer for US generics, was just elected chair of the Association of Accessible Medicines’ board of directors, giving her a commanding view of some of the most momentous events for the generic industry in the coming year, including the early implementation of the Inflation Reduction Act’s drug pricing provisions and the launch of biosimilars for the biggest Rx product in the world, Humira.

The Pink Sheet caught up with Baeder at the sidelines of the AAM’s annual meeting in Orlando on 14 February

More from Biosimilars

More from Conferences

Trump’s Tariffs Will Lead To ‘Instability’ And ‘Less Investment’ In UK

 

While the pharma industry appears to be exempt from US tariffs imposed by President Trump, a member of the UK House of Lords says the details are unknown and warned that uncertainty “leads to less investment” in business as a whole.

UK Health Secretary Admits VPAG ‘More Expensive’ Than Expected & Needs To Be ‘Resolved’

 

The UK government has listened to industry concerns about high clawback rates under the voluntary scheme and will review it in June in a bid to resolve the issue and “move on to bigger and more important things,” health secretary Wes Streeting says.

England’s NICE Wants Industry Involvement In HTA Sandbox Projects

 

Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.